Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge: Key Highlights From the Canadian Thoracic Society (CTS) Position Statement

Samir Gupta; Jane Batt; Jean Bourbeau; Kenneth R. Chapman; Andrea Gershon; John Granton; Nathan Hambly; Paul Hernandez; Martin Kolb; Sanjay Mehta; Lisa Mielniczuk; Steeve Provencher; Anne L. Stephenson; John Swiston; D. Elizabeth Tullis; Nicholas T. Vozoris; Joshua Wald; Jason Weatherald; Mohit Bhutani

doi:10.1016/j.chest.2020.07.018

Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge: Key Highlights From the Canadian Thoracic Society (CTS) Position Statement

Samir Gupta, Jane Batt, Jean Bourbeau, Kenneth R. Chapman, Andrea Gershon, John Granton, Nathan Hambly, Paul Hernandez, Martin Kolb, Sanjay Mehta, Lisa Mielniczuk, Steeve Provencher, Anne L. Stephenson, John Swiston, D. Elizabeth Tullis, Nicholas T. Vozoris, Joshua Wald, Jason Weatherald, Mohit Bhutani

Nursing

Research output: Contribution to journal › Editorial › peer-review

9 Citations (Scopus)

Original language	English
Pages (from-to)	2270-2274
Number of pages	5
Journal	Chest
Volume	158
Issue number	6
DOIs	https://doi.org/10.1016/j.chest.2020.07.018
Publication status	Published - Dec 2020

ASJC Scopus Subject Areas

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.chest.2020.07.018

Cite this

Gupta, S., Batt, J., Bourbeau, J., Chapman, K. R., Gershon, A., Granton, J., Hambly, N., Hernandez, P., Kolb, M., Mehta, S., Mielniczuk, L., Provencher, S., Stephenson, A. L., Swiston, J., Tullis, D. E., Vozoris, N. T., Wald, J., Weatherald, J., & Bhutani, M. (2020). Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge: Key Highlights From the Canadian Thoracic Society (CTS) Position Statement. Chest, 158(6), 2270-2274. https://doi.org/10.1016/j.chest.2020.07.018

Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge: Key Highlights From the Canadian Thoracic Society (CTS) Position Statement. / Gupta, Samir; Batt, Jane; Bourbeau, Jean et al.
In: Chest, Vol. 158, No. 6, 12.2020, p. 2270-2274.

Research output: Contribution to journal › Editorial › peer-review

Gupta, S, Batt, J, Bourbeau, J, Chapman, KR, Gershon, A, Granton, J, Hambly, N, Hernandez, P, Kolb, M, Mehta, S, Mielniczuk, L, Provencher, S, Stephenson, AL, Swiston, J, Tullis, DE, Vozoris, NT, Wald, J, Weatherald, J & Bhutani, M 2020, 'Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge: Key Highlights From the Canadian Thoracic Society (CTS) Position Statement', Chest, vol. 158, no. 6, pp. 2270-2274. https://doi.org/10.1016/j.chest.2020.07.018

@article{d6a9c58925c5428d8e0481e3e61d66a1,

title = "Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge: Key Highlights From the Canadian Thoracic Society (CTS) Position Statement",

author = "Samir Gupta and Jane Batt and Jean Bourbeau and Chapman, {Kenneth R.} and Andrea Gershon and John Granton and Nathan Hambly and Paul Hernandez and Martin Kolb and Sanjay Mehta and Lisa Mielniczuk and Steeve Provencher and Stephenson, {Anne L.} and John Swiston and Tullis, {D. Elizabeth} and Vozoris, {Nicholas T.} and Joshua Wald and Jason Weatherald and Mohit Bhutani",

note = "Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: S. G. reports grants and personal fees from Ontario Lung Association (OLA), outside the submitted work. J. Ba. reports grants from the Canadian Institutes of Health Research (CIHR), Social Sciences and Humanities Research Council of Canada, OLA, outside the submitted work. K. R. C. reports grants from Amgen, grants and personal fees from Astra-Zeneca, grants and personal fees from Boehringer-Ingelheim (BI), personal fees from CSL Behring, grants and personal fees from GlaxoSmithKline (GSK), grants and personal fees from Grifols, grants and personal fees from Kamada, personal fees from Takeda, grants from Vertex, grants and personal fees from Mereo Biopharma, grants and personal fees from Novartis, grants and personal fees from Sanofi, grants and personal fees from Regeneron, outside the submitted work. J. Bo. reports grants from Canadian Respiratory Research Network, grants and personal fees from AZ, grants and personal fees from BI, grants and personal fees from GSK, grants from CIHR, grants from Respiratory Health Network of the Fonds de la recherche en sant{\'e} du Qu{\'e}bec, personal fees from CTS, personal fees from CHEST, grants and personal fees from Grifols, grants and personal fees from Novartis, grants and personal fees from Trudell, outside the submitted work. A. G. reports grants from CIHR and is a member of the Board of Directors of the Physicians{\textquoteright} Services Inc. Foundation in Ontario. J. G. reports grants from Bayer and Actelion/Janssen, outside the submitted work. A member of steering committee for clinical trials sponsored by United Therapeutics and Actelion/Janssen, outside the submitted work. N. H. reports grants and personal fees from Actelion, Bayer, BI, and Hoffman-La Roche Ltd. and personal fees from Novartis, outside the submitted work. P. H. reports grants from CIHR, Lung Association of Nova Scotia, Nova Scotia Health Authority Research Fund, AZ, BI, Cyclomedica, Grifols, Respivant, and Vertex; and personal fees from Actelion, AZ, BI, GSK, Novartis, Sanofi-Aventis, and Trudell, outside the submitted work. M. K. reports grants and personal fees from BI and Hoffman-La Roche Ltd. GSK, Gilead and Prometic, grants from Actelion, Respivert, Alkermes and Pharmaxis, and personal fees from Genoa, Indalo and Third Pole, outside the submitted work. S. M. reports grants from Heart and Stroke Foundation of Ontario/Canada, OLA, Academic Medical Organization of Southwest Ontario, CIHR, Bellerophon, Eiger, Reata, and United Therapeutics; grants and personal fees from Actelion-Janssen and Bayer, outside the submitted work. L. M. reports grants from AZ, Bayer, Janssen, and personal and speaker fees from AZ, Bayer, Janssen, Novartis, outside the submitted work. S. P. reports grants from AZ, Janssen and Resverlogix, outside the submitted work. A. L. S. reports grants from Cystic Fibrosis Canada, US Cystic Fibrosis Foundation; and personal fees from Vertex Pharmaceuticals and Cystic Fibrosis Canada, outside of the submitted work. J. S. reports grants and personal fees from Actelion, Johnson & Johnson, Bayer, Unither, and United Therapeutics, outside the submitted work. D. E. T. reports grants from Bayer, BI, Celtaxis, Corbus, Proteostasis, Spyryx and Vertex Pharmaceuticals and personal fees from Horizon, Proteostasis, Vertex, outside the submitted work. J. Wa. reports personal fees from GSK, grant from Fisher & Paykel, outside the submitted work. J. We. reports grants from CIHR, Lung Association of Alberta and NWT, Heart & Stroke Foundation of Canada, European Respiratory Society, CTS, Canadian Vascular Network; grants and personal fees from Actelion; grants and personal fees from Janssen; personal fees from Novartis and Bayer, outside the submitted work. M. B. reports personal fees and grants from AZ, BI, GSK, Novartis, Sanofi-Genzyme, CIHR, Alberta Innovates Health Solutions, outside the submitted work. None declared (N. T. V.), Other contributions: We acknowledge the Lung Health Foundation for supporting the COPD estimates in this statement. Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: S. G. reports grants and personal fees from Ontario Lung Association (OLA), outside the submitted work. J. Ba. reports grants from the Canadian Institutes of Health Research (CIHR), Social Sciences and Humanities Research Council of Canada , OLA, outside the submitted work. K. R. C. reports grants from Amgen , grants and personal fees from Astra-Zeneca, grants and personal fees from Boehringer-Ingelheim (BI), personal fees from CSL Behring, grants and personal fees from GlaxoSmithKline (GSK), grants and personal fees from Grifols, grants and personal fees from Kamada, personal fees from Takeda , grants from Vertex, grants and personal fees from Mereo Biopharma, grants and personal fees from Novartis , grants and personal fees from Sanofi , grants and personal fees from Regeneron, outside the submitted work. J. Bo. reports grants from Canadian Respiratory Research Network, grants and personal fees from AZ, grants and personal fees from BI, grants and personal fees from GSK, grants from CIHR, grants from Respiratory Health Network of the Fonds de la recherche en sant{\'e} du Qu{\'e}bec, personal fees from CTS, personal fees from CHEST, grants and personal fees from Grifols, grants and personal fees from Novartis, grants and personal fees from Trudell, outside the submitted work. A. G. reports grants from CIHR and is a member of the Board of Directors of the Physicians{\textquoteright} Services Inc. Foundation in Ontario. J. G. reports grants from Bayer and Actelion/Janssen, outside the submitted work. A member of steering committee for clinical trials sponsored by United Therapeutics and Actelion/Janssen, outside the submitted work. N. H. reports grants and personal fees from Actelion, Bayer, BI, and Hoffman-La Roche Ltd. and personal fees from Novartis, outside the submitted work. P. H. reports grants from CIHR, Lung Association of Nova Scotia, Nova Scotia Health Authority Research Fund, AZ, BI, Cyclomedica, Grifols, Respivant, and Vertex; and personal fees from Actelion, AZ, BI, GSK, Novartis, Sanofi-Aventis, and Trudell, outside the submitted work. M. K. reports grants and personal fees from BI and Hoffman-La Roche Ltd., GSK, Gilead and Prometic, grants from Actelion, Respivert, Alkermes and Pharmaxis, and personal fees from Genoa, Indalo and Third Pole, outside the submitted work. S. M. reports grants from Heart and Stroke Foundation of Ontario/Canada, OLA, Academic Medical Organization of Southwest Ontario, CIHR, Bellerophon, Eiger, Reata, and United Therapeutics; grants and personal fees from Actelion-Janssen and Bayer, outside the submitted work. L. M. reports grants from AZ, Bayer, Janssen, and personal and speaker fees from AZ, Bayer, Janssen, Novartis, outside the submitted work. S. P. reports grants from AZ, Janssen and Resverlogix, outside the submitted work. A. L. S. reports grants from Cystic Fibrosis Canada, US Cystic Fibrosis Foundation; and personal fees from Vertex Pharmaceuticals and Cystic Fibrosis Canada, outside of the submitted work. J. S. reports grants and personal fees from Actelion, Johnson & Johnson, Bayer, Unither, and United Therapeutics, outside the submitted work. D. E. T. reports grants from Bayer, BI, Celtaxis, Corbus, Proteostasis, Spyryx and Vertex Pharmaceuticals and personal fees from Horizon, Proteostasis, Vertex, outside the submitted work. J. Wa. reports personal fees from GSK, grant from Fisher & Paykel, outside the submitted work. J. We. reports grants from CIHR, Lung Association of Alberta and NWT, Heart & Stroke Foundation of Canada, European Respiratory Society, CTS, Canadian Vascular Network; grants and personal fees from Actelion; grants and personal fees from Janssen; personal fees from Novartis and Bayer, outside the submitted work. M. B. reports personal fees and grants from AZ, BI, GSK, Novartis, Sanofi-Genzyme, CIHR, Alberta Innovates Health Solutions, outside the submitted work. None declared (N. T. V.) ",

year = "2020",

month = dec,

doi = "10.1016/j.chest.2020.07.018",

language = "English",

volume = "158",

pages = "2270--2274",

journal = "Chest",

issn = "0012-3692",

publisher = "American College of Chest Physicians",

number = "6",

}

TY - JOUR

T1 - Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge

T2 - Key Highlights From the Canadian Thoracic Society (CTS) Position Statement

AU - Gupta, Samir

AU - Batt, Jane

AU - Bourbeau, Jean

AU - Chapman, Kenneth R.

AU - Gershon, Andrea

AU - Granton, John

AU - Hambly, Nathan

AU - Hernandez, Paul

AU - Kolb, Martin

AU - Mehta, Sanjay

AU - Mielniczuk, Lisa

AU - Provencher, Steeve

AU - Stephenson, Anne L.

AU - Swiston, John

AU - Tullis, D. Elizabeth

AU - Vozoris, Nicholas T.

AU - Wald, Joshua

AU - Weatherald, Jason

AU - Bhutani, Mohit

N1 - Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: S. G. reports grants and personal fees from Ontario Lung Association (OLA), outside the submitted work. J. Ba. reports grants from the Canadian Institutes of Health Research (CIHR), Social Sciences and Humanities Research Council of Canada, OLA, outside the submitted work. K. R. C. reports grants from Amgen, grants and personal fees from Astra-Zeneca, grants and personal fees from Boehringer-Ingelheim (BI), personal fees from CSL Behring, grants and personal fees from GlaxoSmithKline (GSK), grants and personal fees from Grifols, grants and personal fees from Kamada, personal fees from Takeda, grants from Vertex, grants and personal fees from Mereo Biopharma, grants and personal fees from Novartis, grants and personal fees from Sanofi, grants and personal fees from Regeneron, outside the submitted work. J. Bo. reports grants from Canadian Respiratory Research Network, grants and personal fees from AZ, grants and personal fees from BI, grants and personal fees from GSK, grants from CIHR, grants from Respiratory Health Network of the Fonds de la recherche en santé du Québec, personal fees from CTS, personal fees from CHEST, grants and personal fees from Grifols, grants and personal fees from Novartis, grants and personal fees from Trudell, outside the submitted work. A. G. reports grants from CIHR and is a member of the Board of Directors of the Physicians’ Services Inc. Foundation in Ontario. J. G. reports grants from Bayer and Actelion/Janssen, outside the submitted work. A member of steering committee for clinical trials sponsored by United Therapeutics and Actelion/Janssen, outside the submitted work. N. H. reports grants and personal fees from Actelion, Bayer, BI, and Hoffman-La Roche Ltd. and personal fees from Novartis, outside the submitted work. P. H. reports grants from CIHR, Lung Association of Nova Scotia, Nova Scotia Health Authority Research Fund, AZ, BI, Cyclomedica, Grifols, Respivant, and Vertex; and personal fees from Actelion, AZ, BI, GSK, Novartis, Sanofi-Aventis, and Trudell, outside the submitted work. M. K. reports grants and personal fees from BI and Hoffman-La Roche Ltd. GSK, Gilead and Prometic, grants from Actelion, Respivert, Alkermes and Pharmaxis, and personal fees from Genoa, Indalo and Third Pole, outside the submitted work. S. M. reports grants from Heart and Stroke Foundation of Ontario/Canada, OLA, Academic Medical Organization of Southwest Ontario, CIHR, Bellerophon, Eiger, Reata, and United Therapeutics; grants and personal fees from Actelion-Janssen and Bayer, outside the submitted work. L. M. reports grants from AZ, Bayer, Janssen, and personal and speaker fees from AZ, Bayer, Janssen, Novartis, outside the submitted work. S. P. reports grants from AZ, Janssen and Resverlogix, outside the submitted work. A. L. S. reports grants from Cystic Fibrosis Canada, US Cystic Fibrosis Foundation; and personal fees from Vertex Pharmaceuticals and Cystic Fibrosis Canada, outside of the submitted work. J. S. reports grants and personal fees from Actelion, Johnson & Johnson, Bayer, Unither, and United Therapeutics, outside the submitted work. D. E. T. reports grants from Bayer, BI, Celtaxis, Corbus, Proteostasis, Spyryx and Vertex Pharmaceuticals and personal fees from Horizon, Proteostasis, Vertex, outside the submitted work. J. Wa. reports personal fees from GSK, grant from Fisher & Paykel, outside the submitted work. J. We. reports grants from CIHR, Lung Association of Alberta and NWT, Heart & Stroke Foundation of Canada, European Respiratory Society, CTS, Canadian Vascular Network; grants and personal fees from Actelion; grants and personal fees from Janssen; personal fees from Novartis and Bayer, outside the submitted work. M. B. reports personal fees and grants from AZ, BI, GSK, Novartis, Sanofi-Genzyme, CIHR, Alberta Innovates Health Solutions, outside the submitted work. None declared (N. T. V.), Other contributions: We acknowledge the Lung Health Foundation for supporting the COPD estimates in this statement. Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: S. G. reports grants and personal fees from Ontario Lung Association (OLA), outside the submitted work. J. Ba. reports grants from the Canadian Institutes of Health Research (CIHR), Social Sciences and Humanities Research Council of Canada , OLA, outside the submitted work. K. R. C. reports grants from Amgen , grants and personal fees from Astra-Zeneca, grants and personal fees from Boehringer-Ingelheim (BI), personal fees from CSL Behring, grants and personal fees from GlaxoSmithKline (GSK), grants and personal fees from Grifols, grants and personal fees from Kamada, personal fees from Takeda , grants from Vertex, grants and personal fees from Mereo Biopharma, grants and personal fees from Novartis , grants and personal fees from Sanofi , grants and personal fees from Regeneron, outside the submitted work. J. Bo. reports grants from Canadian Respiratory Research Network, grants and personal fees from AZ, grants and personal fees from BI, grants and personal fees from GSK, grants from CIHR, grants from Respiratory Health Network of the Fonds de la recherche en santé du Québec, personal fees from CTS, personal fees from CHEST, grants and personal fees from Grifols, grants and personal fees from Novartis, grants and personal fees from Trudell, outside the submitted work. A. G. reports grants from CIHR and is a member of the Board of Directors of the Physicians’ Services Inc. Foundation in Ontario. J. G. reports grants from Bayer and Actelion/Janssen, outside the submitted work. A member of steering committee for clinical trials sponsored by United Therapeutics and Actelion/Janssen, outside the submitted work. N. H. reports grants and personal fees from Actelion, Bayer, BI, and Hoffman-La Roche Ltd. and personal fees from Novartis, outside the submitted work. P. H. reports grants from CIHR, Lung Association of Nova Scotia, Nova Scotia Health Authority Research Fund, AZ, BI, Cyclomedica, Grifols, Respivant, and Vertex; and personal fees from Actelion, AZ, BI, GSK, Novartis, Sanofi-Aventis, and Trudell, outside the submitted work. M. K. reports grants and personal fees from BI and Hoffman-La Roche Ltd., GSK, Gilead and Prometic, grants from Actelion, Respivert, Alkermes and Pharmaxis, and personal fees from Genoa, Indalo and Third Pole, outside the submitted work. S. M. reports grants from Heart and Stroke Foundation of Ontario/Canada, OLA, Academic Medical Organization of Southwest Ontario, CIHR, Bellerophon, Eiger, Reata, and United Therapeutics; grants and personal fees from Actelion-Janssen and Bayer, outside the submitted work. L. M. reports grants from AZ, Bayer, Janssen, and personal and speaker fees from AZ, Bayer, Janssen, Novartis, outside the submitted work. S. P. reports grants from AZ, Janssen and Resverlogix, outside the submitted work. A. L. S. reports grants from Cystic Fibrosis Canada, US Cystic Fibrosis Foundation; and personal fees from Vertex Pharmaceuticals and Cystic Fibrosis Canada, outside of the submitted work. J. S. reports grants and personal fees from Actelion, Johnson & Johnson, Bayer, Unither, and United Therapeutics, outside the submitted work. D. E. T. reports grants from Bayer, BI, Celtaxis, Corbus, Proteostasis, Spyryx and Vertex Pharmaceuticals and personal fees from Horizon, Proteostasis, Vertex, outside the submitted work. J. Wa. reports personal fees from GSK, grant from Fisher & Paykel, outside the submitted work. J. We. reports grants from CIHR, Lung Association of Alberta and NWT, Heart & Stroke Foundation of Canada, European Respiratory Society, CTS, Canadian Vascular Network; grants and personal fees from Actelion; grants and personal fees from Janssen; personal fees from Novartis and Bayer, outside the submitted work. M. B. reports personal fees and grants from AZ, BI, GSK, Novartis, Sanofi-Genzyme, CIHR, Alberta Innovates Health Solutions, outside the submitted work. None declared (N. T. V.)

PY - 2020/12

Y1 - 2020/12

UR - http://www.scopus.com/inward/record.url?scp=85096522448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096522448&partnerID=8YFLogxK

U2 - 10.1016/j.chest.2020.07.018

DO - 10.1016/j.chest.2020.07.018

M3 - Editorial

C2 - 32693101

AN - SCOPUS:85096522448

SN - 0012-3692

VL - 158

SP - 2270

EP - 2274

JO - Chest

JF - Chest

IS - 6

ER -

Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge: Key Highlights From the Canadian Thoracic Society (CTS) Position Statement

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Cite this